The recent congressional hearings held by House and Senate committees are being interpreted as a good indication that bi-partisan support can be mustered to pass legislation that would strengthen FDA oversight of compounders.
Mr. Romney again declines to offer specifics, instead suggesting it can be left to the cooperation of a Congress that could not even pass an economic plan developed by their own bi-partisan panel as a path forward in dire economic times.